Results 261 to 270 of about 5,770,101 (353)

Rewiring Dendritic Cell Immunity: The β-Catenin-TIM-3 Axis as a Target to Improve DC Cancer Vaccines. [PDF]

Cancers (Basel)
Fu C, Ma T, Zhou L, Mi QS, Jiang A.
europepmc   +1 more source

A Rationally Engineered Spleen-Tropic One-Component Lipid-mRNA Complex (OncoLRC) for Cancer Vaccines. [PDF]

Adv Sci (Weinh)
Yin Q, Zhang C, Li J, Huang K, Qiu M.
europepmc   +1 more source

Influenza and Human Papillomavirus Vaccine Utilisation in Vulnerable Urban Youth in Edmonton, Alberta, Canada

The International Journal of Health Planning and Management, EarlyView.
ABSTRACT Introduction This project explores influenza and human papillomavirus (HPV) vaccine utilisation among a multi‐ethnic group of youth (aged 11–23 years) in Edmonton, Alberta, Canada. Method Using a cross‐sectional design and purposive sampling, influenza vaccine utilisation over 3 years was assessed via questionnaire.
Sarah Deck, Se Lim Jang, Rachel Harris, Fariba Kolahdooz, Moutasem Zakkar, Sangita Sharma   +5 more
wiley   +1 more source

Therapeutic Cancer Vaccines in Colorectal Cancer: Platforms, Mechanisms, and Combinations. [PDF]

Cancers (Basel)
Gallio C, Esposito L, Passardi A.
europepmc   +1 more source

Increased cervical cancer incidence in the target age of screening—Variation by mode of detection

International Journal of Cancer, EarlyView.
What's New? Cervical cancer rates have risen in several high‐income countries despite advances in screening. Here, using data on cervical cancer diagnoses between 1996 and 2022 in Finland, the authors examined incidence trends according to detection mode—screening, between screenings, or outside screening programs—with attention to the role of human ...
Jenna Snellman, Maiju Pankakoski, Sirpa Heinävaara, Veli‐Matti Partanen, Maija Vahteristo   +4 more
wiley   +1 more source

Eliciting antitumor immunity via therapeutic cancer vaccines. [PDF]

Cell Mol Immunol
Peng K, Zhao X, Fu YX, Liang Y.
europepmc   +1 more source

Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage

International Journal of Cancer, EarlyView.
What's New? Effective cervical cancer prevention centers around screening and testing for human papillomavirus (HPV) infection. With birth cohorts of HPV‐vaccinated women now reaching screening‐eligible ages, however, the best means to maintaining cost‐effective cervical cancer screening is unclear.
Tiago M. de Carvalho, Johannes Berkhof, Johannes A. Bogaards   +2 more
wiley   +1 more source

A systematic review of the efficacy of cancer vaccines in advanced breast cancer. [PDF]

Breast Cancer
Charalampopoulou A, Filippatos C, Malandrakis P, Zagouri F, Gavriatopoulou M, Ntanasis-Stathopoulos I.   +5 more
europepmc   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Strategic Advances in Targeted Delivery Carriers for Therapeutic Cancer Vaccines. [PDF]

Int J Mol Sci
Wu J, Liang J, Zhang Y, Dong C, Tan D, Wang H, Zheng Y, He Q.   +7 more
europepmc   +1 more source